A Randomized, Double-blind, Placebo-controlled, First-in-Human Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Ad26-ZIKV-001 (Primary)
- Indications Zika virus infection
- Focus Adverse reactions; First in man
- Sponsors Janssen Vaccines and Prevention B.V
- 06 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Jul 2018 Planned End Date changed from 15 Aug 2019 to 31 Oct 2019.
- 22 May 2018 Planned End Date changed from 27 Jun 2019 to 15 Aug 2019.